Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05654493 · ClinicalTrials.gov registry record
Use of Micropulse Trans-Scleral Cyclophotocoagulation Laser (MP-TSCPC) for Glaucoma Patients
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 65
- Enrollment target
NCT05654493: Completed study, sponsored by Mayo Clinic.
NCT05654493 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 65 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05654493 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 65 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the clinical outcomes of the Micropulse Trans-Scleral Cyclophotocoagulation Laser (MP-TSCPC) after 1 day, 1 week,1 month, 3 months, 6 months and one year of follow-up, with the intent to evaluate the efficacy of using MP-TSCPC to treat glaucoma patients.
Primary Outcome
Change in intraocular pressure (IOP), reported in millimeters of mercury (mm Hg)
Interventions
- DEVICE MicroPulse Transscleral Laser Therapy using revised P3 Delivery Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2022-04-18 |
| Est. Completion | 2023-06-30 |
What the finished NCT05654493 record still lists
NCT05654493 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 65 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which MicroPulse Transscleral Laser Therapy using revised P3 Delivery Device is the first listed.
NCT05654493 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05654493 about?
NCT05654493 is a clinical study titled "Use of Micropulse Trans-Scleral Cyclophotocoagulation Laser (MP-TSCPC) for Glaucoma Patients". The purpose of this study is to evaluate the clinical outcomes of the Micropulse Trans-Scleral Cyclophotocoagulation Laser (MP-TSCPC) after 1 day, 1 week,1 month, 3 months, 6 months and one year of follow-up, with the intent to evaluate the efficacy of using MP-TSCPC to treat glaucoma patients.
What is the current status of trial NCT05654493?
This trial is currently completed. The enrollment target is 65 participants. The study started on 2022-04-18. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT05654493?
The interventions under investigation include: MicroPulse Transscleral Laser Therapy using revised P3 Delivery Device (DEVICE).
Who is sponsoring clinical trial NCT05654493?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI